RET (G810S)

RET · Variant type: point · HGVS: p.G810S

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Selpercatinib	98.3%	1.6%	96.72
2	Pralsetinib	97.8%	2.2%	93.43
3	Tivozanib	97.3%	2.7%	92.42
4	Alpelisib	87.2%	12.8%	97.22
5	Sorafenib	86.6%	13.4%	96.72
6	Entrectinib	85.9%	14.1%	93.69
7	Tenalisib	85.8%	14.2%	97.98
8	Repotrectinib	84.0%	16.0%	84.21
9	Ripretinib	79.6%	20.4%	92.95
10	Erdafitinib	78.0%	22.0%	95.71
11	Fedratinib	75.1%	24.9%	96.21
12	Apatinib	67.9%	32.1%	97.73
13	Futibatinib	57.0%	43.0%	98.48
14	Gilteritinib	54.3%	45.7%	88.97
15	Avapritinib	52.2%	47.8%	97.73
16	Sunitinib	48.8%	51.2%	91.73
17	Capivasertib	34.9%	65.1%	96.48
18	Upadacitinib	34.4%	65.6%	97.98
19	Defactinib	29.3%	70.7%	92.68
20	Pexidartinib	27.4%	72.6%	99.49
21	Canertinib	21.5%	78.5%	96.49
22	Pirtobrutinib	19.5%	80.5%	99.49
23	Vandetanib	18.6%	81.4%	95.74
24	Pacritinib	14.3%	85.7%	88.64
25	Abrocitinib	14.0%	86.0%	99.50

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Selpercatinib	98.3%	100.0%	-1.7%
Pralsetinib	97.8%	100.0%	-2.2%
Tivozanib	97.3%	99.7%	-2.4%
Alpelisib	87.2%	99.6%	-12.5%
Sorafenib	86.6%	94.0%	-7.4%
Entrectinib	85.9%	99.6%	-13.7%
Tenalisib	85.8%	98.5%	-12.7%
Repotrectinib	84.0%	—	—
Ripretinib	79.6%	—	—
Erdafitinib	78.0%	94.7%	-16.6%
Fedratinib	75.1%	99.9%	-24.8%
Apatinib	67.9%	—	—
Futibatinib	57.0%	97.7%	-40.6%
Gilteritinib	54.3%	100.0%	-45.7%
Avapritinib	52.2%	—	—
Sunitinib	48.8%	97.2%	-48.4%
Capivasertib	34.9%	—	—
Upadacitinib	34.4%	—	—
Defactinib	29.3%	—	—
Pexidartinib	27.4%	—	—
Canertinib	21.5%	—	—
Pirtobrutinib	19.5%	—	—
Vandetanib	18.6%	98.6%	-80.0%
Pacritinib	14.3%	—	—
Abrocitinib	14.0%	—	—

Cancer	Organ	Source
carcinoma_lung	Lung	ref
carcinoma_thyroid	Thyroid	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.4ms